W14.362 Sex-specific effect of APOAV variant VAL153S met on plasma levels of HDL-cholesterol

2004 ◽  
Vol 5 (1) ◽  
pp. 84
Author(s):  
J HUBACEK
Keyword(s):  
Plasma Levels ◽  
Specific Effect ◽  
Hdl Cholesterol

W14.362 Sex-specific effect of APOAV variant VAL153® met on plasma levels of HDL-cholesterol

2004 ◽  
Vol 5 (1) ◽  
pp. 84
Author(s):  
J. Hubacek ◽  
Z. Skodova ◽  
V. Adamkova ◽  
V. Lanska ◽  
R. Poledne
Keyword(s):  
Plasma Levels ◽  
Specific Effect ◽  
Hdl Cholesterol

A comparison of the effects of fish oil and flaxseed oil on cardiac allograft chronic rejection in rats

2008 ◽  
Vol 294 (3) ◽  
pp. H1452-H1458 ◽  
Author(s):  
Rgia A. Othman ◽  
Miyoung Suh ◽  
Gabor Fischer ◽  
Nazila Azordegan ◽  
Natalie Riediger ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Body Weight ◽  
Fish Oil ◽  
Plasma Levels ◽  
Chronic Rejection ◽  
Graft Function ◽  
Hdl Cholesterol ◽  
Treated Group ◽  
Flaxseed Oil ◽  
Cardiac Allograft

Both fish and flaxseed oils are major sources of different n-3 fatty acids. Beneficial effects of fish oil on posttransplantation complications have been reported. The current study aimed to compare the effects of flaxseed and fish oils in a rat cardiac allograft model. Male Fischer and Lewis rats were used as donors and recipients, respectively, to generate a heterotopic cardiac allograft model. Animals were randomly assigned into three groups and fed a diet supplemented with 1) 5% (wt/wt) safflower oil (control, n = 7), 2) 5% (wt/wt) flaxseed oil ( n = 8), or 3) 2% (wt/wt) fish oil ( n = 7), and an intraperitoneal injection of cyclosporine A (CsA; 1.5 mg·kg−1·day−1) over 12 wk. Body weight, blood pressure, plasma levels of lipids, CsA, select cytokines, as well as graft function and chronic rejection features were assessed. Body weight and blood CsA levels were similar among the groups. Relative to controls, both treated groups had lower systolic and diastolic blood pressure and plasma levels of macrophage chemotactic protein-1. Treatment with fish oil significantly ( P < 0.05) lowered plasma levels of triglycerides, total cholesterol, and LDL-cholesterol. HDL-cholesterol concentrations were significantly higher ( P < 0.05) in the flaxseed oil-treated group compared with the other two groups. Both flaxseed oil and fish oil may provide similar biochemical, hemodynamic, and inflammatory benefits after heart transplantation; however, neither of the oils was able to statistically significantly impact chronic rejection or histological evidence of apparent cyclosporine-induced nephrotoxicity in this model.

Plasma levels of antibodies against oxidized LDL are inherited but not associated with HDL-cholesterol level in families with early coronary heart disease

2012 ◽  
Vol 224 (1) ◽  
pp. 123-128 ◽  
Author(s):  
Timo Paavola ◽  
Tiia Kangas-Kontio ◽  
Tuire Salonurmi ◽  
Sanna Kuusisto ◽  
Tuija Huusko ◽  
...  
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Cholesterol Level ◽  
Plasma Levels ◽  
Oxidized Ldl ◽  
Hdl Cholesterol

Cardiometabolic Risk Factors in Men with Elevated Macroprolactin Content: A Pilot Study

2019 ◽  
Vol 129 (01) ◽  
pp. 7-13
Author(s):  
Robert Krysiak ◽  
Witold Szkróbka ◽  
Bogusław Okopień
Keyword(s):  
Uric Acid ◽  
Insulin Sensitivity ◽  
Plasma Levels ◽  
Cardiometabolic Risk ◽  
Plasma Lipids ◽  
Plasma Concentrations ◽  
Hdl Cholesterol ◽  
High Sensitivity ◽  
Hydroxyvitamin D ◽  
25 Hydroxyvitamin D

Abstract Background Macroprolactinemia is a condition associated with the presence of large amounts of high molecular weight complexes of prolactin. Despite high prevalence, clinical significance of macroprolactin remains poorly understood. Objective The aim of this study was to assess cardiometabolic risk in men with isolated macroprolactinemia. Methods The study population included 11 men with isolated macroprolactinemia, 14 subjects with monomeric hyperprolactinemia and 14 men with prolactin levels within the reference range. Glucose homeostasis markers, plasma lipids, as well as plasma levels of uric acid, high-sensitivity C-reactive protein (hsCRP), fibrinogen, homocysteine and 25-hydroxyvitamin D were determined in all included patients. Results Compared to healthy counterparts, men with isolated macroprolactinemia had higher levels of 2-h postchallenge glucose, hsCRP and fibrinogen, lower levels of 25-hydroxyvitamin D and reduced insulin sensitivity. Patients with monomeric hyperprolactinemia were characterized by increased plasma levels of 2-h postchallenge glucose, triglycerides, uric acid, hsCRP, fibrinogen and homocysteine, reduced insulin sensitivity and decreased plasma concentrations of HDL cholesterol and 25-hydroxyvitamin D. Subjects with isolated macroprolactinemia differed from patients with monomeric hyperprolactinemia in postchallenge plasma glucose, insulin sensitivity, uric acid, hsCRP, fibrinogen, homocysteine and 25-hydroxyvitamin D. In men with monomeric hyperprolactinemia, uric acid, hsCRP, fibrinogen, homocysteine and 25-hydroxyvitamin D, while in men with elevated levels of macroprolactin, uric acid, hsCRP, fibrinogen and 25-hydroxyvitamin D correlated with a content of monomeric prolactin or macroprolactin, respectively, as well as with a degree of insulin sensitivity. Conclusions The obtained results suggest that macroprolactinemia may increase cardiometabolic risk but to a lesser extent than monomeric hyperprolactinemia.

P6191Proprotein convertase subtilisin/kexin type 9 (PCSK9) plasma levels are associated with the metabolic syndrome in patients with stable coronary artery disease

2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
C Caselli ◽  
R Ragusa ◽  
S Del Turco ◽  
G Basta ◽  
A Saraste ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Metabolic Syndrome ◽  
Coronary Artery ◽  
Plasma Levels ◽  
Hdl Cholesterol ◽  
Homa Index ◽  
Cholesterol Levels ◽  
The Metabolic Syndrome ◽  
Artery Disease ◽  
Stable Cad

Abstract Background PCSK9 is a key regulator of serum LDL-cholesterol levels. The relation of PCSK9 with other components of cardiovascular and coronary artery disease (CAD) risk is still debated. Purpose To evaluate the association of PCSK9 plasma levels with cardiovascular and coronary risk profile, in patients with symptoms of suspected stable CAD enrolled in the EVINCI study. Methods PCSK9 was measured in 522 patients (60.4±8.8 years, 318 males) with symptoms of stable CAD Individual risk was characterized by clinical and bio-humoral variables, including lipid/glucose/inflammatory profiles. Obstructive CAD was firstly ruled-in by multimodality non-invasive imaging and, subsequently, assessed by invasive coronary angiography. Results Patients were divided into groups according to PCSK9 quartiles: I (<138 ng/mL), II-III (138–264 ng/mL), and IV (>264 ng/mL) (Table). The prevalence of obstructive CAD at invasive angiography and statin treatment did not differ among groups. Compared with patients in quartile IV, patients in quartile I, had a higher prevalence of metabolic syndrome and higher values of body mass index. Among biomarkers, all cholesterol lipoproteins levels progressively increased from quartile I to IV, while insulin and HOMA index values decreased (Table). At multivariable analyses adjusted for medical treatment, the only clinical or bio-humoral variables independently associated with PCSK9 levels were presence of the metabolic syndrome (Coeff. −0.195, SE 0.05, p<0.0001) and HDL cholesterol levels (Coeff. 0.444, SE 0.06, p<0.0001), respectively. Table 1 Clinical Variables Quartile I Quartile II–III Quartile IV Biomarkers Quartile I Quartile II–III Quartile IV <138 ng/L 138–264 ng/L >264 ng/L <138 ng/L 138–264 ng/L >264 ng/L (n=130) (n=261) (n=131) (n=130) (n=261) (n=131) Age, years 61±9 60±9 61±8 Glucose, mg/dL 110±30 117±41 109±29 Male gender 86 (66) 161 (62) 71 (55) Insulin, mUI/mL 13.3±12.5* 11.3±10.1 10.3±10.1 Family history 38 (29)# 86 (33) 58 (44) HOMA index 3.9±4.5* 3.5±4.1 2.9±3.3 Hypertension 78 (60) 164 (63) 88 (67) Tryglicerides, mg/dL 128±86 128±87 118±68 Hypercholesterolemia 72 (55) 158 (61) 81 (62) Total cholesterol, mg/dL 171±43* 181±45 203±55 Diabetes mellitus 43 (33) 91 (35) 37 (28) LDL, mg/dL 99±36* 104±38 119±45 Metabolic Syndrome 45 (35)# 72 (28) 19 (15) HDL, mg/dL 46±13* 52±15 61±19 BMI, kg/m2 28.02±4.00* 28.03±4.25 26.95±4.56 Total/HDL cholesterol 3.8±1.2* 3.7±1.2 3.5±1.1 Significant CAD at ICA 18 (14) 46 (18) 24 (18) hs-CRP, mg/dL 0.41±0.61 0.39±1.38 0.41±0.83 Statins treatment 68 (52) 143 (55) 58 (44) Interleukin 6, ng/L 1.60±2.75 1.30±2.49 1.30±1.68 Chi square test: #p<0.05. ANOVA: I vs. IV Quartile: *p<0.05. Conclusion In patients with stable CAD, low plasma levels of PCSK9 are associated with the prevalence of metabolic syndrome and its individual components, including, in particular, HDL cholesterol. Acknowledgement/Funding AMGEN grant, EU FP7-CP-FP506 2007 project (grant agreement no. 222915)

Plasma levels of VLDL- + LDL-cholesterol, HDL-cholesterol, triglycerides and apoproteins B and A-I in a healthy population Influence of Several Risk Factors

1980 ◽  
Vol 37 (4) ◽  
pp. 559-568 ◽  
Author(s):  
E. Dedonder-Decoopman ◽  
C. Fievet-Desreumaux ◽  
E. Campos ◽  
S. Moulin ◽  
P. Dewailly ◽  
...  
Keyword(s):  
Risk Factors ◽  
Plasma Levels ◽  
Ldl Cholesterol ◽  
Hdl Cholesterol ◽  
Healthy Population

scholarly journals M204. ULTRA-RESISTANT SCHIZOPHRENIA IS ASSOCIATED WITH A DELAY TO INITIATE CLOZAPINE AND WITH LESS ABDOMINAL OBESITY. SEX DIFFERENCES IN INSULINEMIA AND LEPTIN LEVELS ARE OBSERVED BETWEEN RESPONDERS AND NOT RESPONDERS

2020 ◽  
Vol 46 (Supplement_1) ◽  
pp. S213-S214
Author(s):  
Guillermo Hönig ◽  
Demián Rodante ◽  
Federico Daray ◽  
Mercedes Izaguirre ◽  
Mariela Lenze ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Waist Circumference ◽  
Clinical Response ◽  
Abdominal Obesity ◽  
Plasma Levels ◽  
Case Control Study ◽  
Hdl Cholesterol ◽  
Case Control ◽  
Factors Associated ◽  
Control Study

Abstract Background 30% patients suffering from schizophrenia fail to obtain therapeutic benefit even after two appropriate antipsychotic trials and are considered resistant. The recommended treatment in these cases is clozapine (CLZ), but only 40% of patients with resistant schizophrenia show clinical response, a condition called ultra-resistance (UR) and defined as the lack of antipsychotic response after 8 to 12 weeks of treatment with at least 400 mg/day of clozapine or plasma levels ≥ 350 ng/ml. The objective of the present study is to identify factors associated with UR in in a group of patients from Argentina. Methods A paired case-control study was conducted, being cases those patients with UR schizophrenia and controls those who responded to CLZ; both groups were matched by age and sex. The response to CLZ was measured using the PANSS (UR was defined with a total score ≥ 80). The following parameters were compared between groups: months of untreated psychosis, months until the introduction of clozapine, body mass index (BMI), waist circumference, fasting blood glucose, insulinemia, triglyceridemia, HDL cholesterol, ultrasensitive C-reactive protein (CRP) and plasma leptin levels. Clozapine and nor-clozapine plasma trough levels were measured by HPLC-MS/MS. Results 9 men (M) and 7 women (W) with the diagnosis of UR schizophrenia were matched with the same number of responders (R) to clozapine. Total PANSS scores (mean ± SD) for each group were as follows: W-R 48.9 ± 11; W-UR 88.4 ± 6 (p &lt; 0.0001); M-R 60.5 ± 7; M-UR 112.8 ± 23 (p &lt; 0.0001). CLZ dose was significantly higher both in W-UR and in M-UR than in paired controls (p &lt; 0.05). Nonsignificant differences were observed for nor-CLZ plasma concentration among groups. Clozapinemia was not different among men but it was significantly higher in W-UR in comparison with W-R (p &lt; 0.05). Significant differences were detected in the amount of months that passed before initiation of CLZ both for women (W-R 140.9 ± 124, W-UR 255.6 ± 153, p &lt; 0.005) and men (M-R 104.0 ± 51. 6 versus M-UR 174.6± 65; p &lt; 0.05). Body mass index (kg/m2) was significantly lower in UR patients: W-R 35.3 ± 6 versus W-UR 26.9 ± 3 (p &lt; 0.05) and M-R 30.6 ± 5 versus M-UR 22.7 ± 4 (p &lt;.005). Waist circumference (cm) was also significantly lower in UR independently of sex: W-R 110.6 ± 12 versus W-UR 98.5 ± 8 (p &lt; 0.05); M-R 113.9 ± 15 versus M-UR 87.4 ± 9 (p &lt;0 .005). Insulinemia (UI/ml) was significantly lower in M-UR than in M-R (16.1± 8 versus 9.4 ± 7, p&lt;0.005) but not in women. Also significant differences were found in leptin levels (pg/ml) in men but not in women (M-R 1824.0 ± 1139 versus M-UR 477.6 ± 692; p &lt; 0.05). No differences were observed in the number of antipsychotics received before CLZ, months of untreated psychosis, fasting glycemia, trygliceridemia, HDL cholesterol, CRP, HbA1c and diastolic or systolic arterial blood pressure. Discussion Time to CLZ initiation could be a critical factor predisposing to UR. The absence of clozapine-induced abdominal obesity and changes in BMI are also to be associated with poor clinical response, independently of plasma drug levels. Differences between ultra-resistant men and women concerning insulin and leptin plasma levels should be further investigated. As far as we know, this is the first paired case-control study aimed to investigate factors associated with CLZ resistance in schizophrenia.

Sign in / Sign up

Export Citation Format

Share Document